ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
Europe’s emerging biotechs: Challenges, opportunities and funding
John Macdonald, Vice President, Venture & Financial Alliances, examines the European biotech sector – its expertise and opportunities, and potential for growth.
Recruiting patients for real-world studies
William Maier, VP Rare Diseases, Drug Development Sciences, considers the benefits of digital recruitment campaigns for recruiting patients for real-world studies.
Communicating for change - creating effective medical communications
Chris O'Toole, VP Commercial Solutions, discusses best practices for medical communications to improve interactions and results.
Why ITT analysis is not always the answer for estimating treatment effects in clinical trials
Dr. Alan Phillips provides his insights on the role of estimands in clinical research.
Clinical Research: One of Ireland's most promising industries
ICON CEO Dr. Steve Cutler discusses clinical research as one of Ireland’s most promising industries in this special supplement on Ireland’s economy that appeared in the weekend edition of the New York Times.
The bottom line: Clinical trials
Nuala Murphy, President Global Specialty Solutions, contributes to the Bottom Line BBC4 podcast about the impact of the COVID-19 vaccine on the clinical trial process and whether these changes could work for other drugs.
Overcoming data flow challenges in cell therapy trials
How data flows in cell therapy studies differ from other studies and strategies to manage the high volume of data in CGT trials is highlighted in this Q&A with ICON expert Olivier Saulin.
Innovation in clinical trial methodologies
In this podcast, Dr. Peter Schueler, Senior VP Drug Development Services, Neurosciences at ICON, talks about topics discussed in a timely new book he edited titled Innovation in Clinical Trial Methodologies.
Pharma’s coming home
Seth Nelson, Senior Director of Patient Recruitment and Clinical Research Services, provides expert commentary on patient centricity during the pandemic.
Lessons from the first generation of cell and gene oncology trials
ICON’s Tamie Joeckel and Brandon Fletcher take us through best practice approaches to CGT studies and discuss what the future could hold for this exciting area.